A Study on the Anticarcinogenic Effects of Calcium Fructoborate

Simple item page
dc.contributor.authorTepedelen B.E.
dc.contributor.authorKorkmaz M.
dc.contributor.authorTatlisumak E.
dc.contributor.authorUluer E.T.
dc.contributor.authorÖlmez E.
dc.contributor.authorDeğerli İ.
dc.contributor.authorSoya E.
dc.contributor.authorİnan S.
dc.date.accessioned2024-07-22T08:10:35Z
dc.date.available2024-07-22T08:10:35Z
dc.date.issued2017
dc.description.abstractEvidences about the preventive and therapeutic effects of boron compounds on cancer have been increasing in the last years. Although calcium fructoborate (CaFB) is used as a nutritional supplement, data about its preventive and therapeutic effects on neoplastic transformations are limited. In the present study, the various concentrations of CaFB were applied to the MDA-MB-231 metastatic breast cancer cell line. First, we examined the cytotoxic effect and IC50 value of CaFB by MTT assay. For the evaluation of the DNA damage, apoptosis and metastatic potential, expression levels of ATM, pATM, PARP, p53, p-p53, caspase-3, caspase-9, and VEGF were investigated by using immunoblotting and immunohistochemical methods. Cell viability was significantly reduced at 50 μM CaFB treatment. pATM, p-p53, and caspase-9 levels increased significantly in all groups; furthermore, there was approximately 12.5-, 2.4-, and 10.7-fold increase, respectively, for 100 μM CaFB treatment. ATM and p53 levels did not change with CaFB treatment, but PARP levels significantly 2.5-fold decreased. While VEGF immunoreactivity decreased in all groups, significant increase in caspase-3 immunoreactivity was observed only in the group treated with 50 μM CaFB (p < 0,001). Our results imply that CaFB may have therapeutic potential as well as preventive benefits in cancer. © 2016, Springer Science+Business Media New York.
dc.identifier.DOI-ID10.1007/s12011-016-0918-6
dc.identifier.issn01634984
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15272
dc.language.isoEnglish
dc.publisherHumana Press Inc.
dc.subjectAnticarcinogenic Agents
dc.subjectBorates
dc.subjectBreast Neoplasms
dc.subjectCell Line, Tumor
dc.subjectDrug Screening Assays, Antitumor
dc.subjectFemale
dc.subjectFructose
dc.subjectHumans
dc.subjectNeoplasm Proteins
dc.subjectATM protein
dc.subjectboric acid
dc.subjectcalcium fructoborate
dc.subjectcaspase 3
dc.subjectcaspase 9
dc.subjectDNA
dc.subjectnicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase
dc.subjectnutrition supplement
dc.subjectprotein p53
dc.subjectunclassified drug
dc.subjectvasculotropin
dc.subjectantineoplastic agent
dc.subjectboric acid
dc.subjectcalcium fructoborate
dc.subjectfructose
dc.subjecttumor protein
dc.subjectapoptosis
dc.subjectArticle
dc.subjectcell viability
dc.subjectcontrolled study
dc.subjectcytotoxicity
dc.subjectDNA damage
dc.subjectfemale
dc.subjecthuman
dc.subjectIC50
dc.subjectimmunoblotting
dc.subjectimmunohistochemistry
dc.subjectimmunoreactivity
dc.subjectMDA-MB-231 cell line
dc.subjectmetastatic breast cancer
dc.subjectMTT assay
dc.subjectprotein expression
dc.subjectanalogs and derivatives
dc.subjectbreast tumor
dc.subjectdrug screening
dc.subjectmetabolism
dc.subjectpathology
dc.subjecttumor cell line
dc.titleA Study on the Anticarcinogenic Effects of Calcium Fructoborate
dc.typeArticle

Files

Collections

Scopus Koleksiyonu